Registry for pancreatic cancer patients getting a specific ablation
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This is a research registry that collects information from adults with pancreatic cancer who are treated with an ablation procedure called irreversible electroporation (IRE). It may help doctors better understand which patients benefit from this approach and how the treatment is used in real life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be older than 18 years.
- You must have been diagnosed with pancreatic cancer.
- Your treating doctor must think you are eligible for soft-tissue ablation (the IRE procedure).
- You cannot have a pacemaker or an implanted defibrillator (ICD).
- You cannot have a non-removable metal implant near the planned treatment area.
- You cannot have had a heart attack within the last 3 months.
- You must be well enough to receive general anesthesia through a breathing tube.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people with advanced pancreatic cancer who have already been treated with a procedure called irreversible electroporation (IRE), which uses electric pulses to kill cancer cells, sometimes along with immunotherapy drugs. The goal is to learn more about how well this combination works and how safe it is.
This is a research registry that collects information from adults with suspected or diagnosed pancreatic cancer. It may help doctors better understand the disease and improve care over time.
This registry collects information about people with advanced pancreatic cancer who are receiving first-line palliative treatment. It helps doctors understand which treatment choices are used and how people do over time.
This study is a registry that collects information about people who need an endoscopy procedure. It may help doctors learn which approaches work best and improve care over time.
This study tests a new treatment combining tumor destruction with heat/cold (ablation) and an immunotherapy drug (PD-1) for people whose pancreatic cancer has spread to the liver. The goal is to help the immune system fight the cancer better.
This registry collects information about patients receiving a specialized procedure called EUS-guided ablation—using heat to destroy abnormal growths in the pancreas and digestive tract. By tracking your care, researchers aim to better understand how effective and safe this treatment is.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.